(NYSE: PFE) stock has been struggling for a while now. In the past 12 months, it has declined by 36%. A lack of growth recently, a dependence on acquisitions, and many question marks have resulted in a lot of investors simply taking a pass on this top healthcare stock.

But could that be a mistake, and could Pfizer return to glory in 10 years and prove to be a great buy again? Here's where the business may be a decade from now, and whether investors should consider buying the stock today.

A decade from now, the makeup of Pfizer's financials is likely going to change significantly. It'll be a surprise if its COVID vaccine generates any meaningful revenue, as concerns relating to the illness are already subsiding today. In 2023, despite a mammoth 70% drop in sales, Comirnaty was still the company's top-selling product, bringing in more than $11.2 billion.

Continue reading

Source Fool.com